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Abstract 
Background: Metoclopramide is a commonly used anti‑emetic drug known to cause extrapyramidal symptoms as 
adverse effects, amongst which are dystonic reactions. These reactions are more frequent at high doses of metoclo‑
pramide, in female patients, children and adults less than 30 years of age. We hereby present the case of a 16 year old 
female who had dystonic reactions from metoclopramide, highlighting its unpredictable nature and the shortcom‑
ings of the management in resource‑limited settings.
Case presentation: A 16 year old female Muslim from the Extreme North of Cameroon with no significant past 
history, was treated for severe malaria and associated refractory vomiting using intravenous quinine and metoclopra‑
mide respectively. She developed dystonic reactions after being administered her second dose of metoclopramide. 
The drug was discontinued and she was administered 8 mg of chlorpheniramine by mouth. Her symptoms resolved 
after 4 h. She was discharged 2 days later with no further complaints.
Conclusions: Metoclopramide causes dystonic reactions which are often unpredictable and is frequently prescribed 
by health providers. This creates an environment of anxiety for the patient and the caregiver, and can result in life 
threatening consequences. Patients on metoclopramide should be monitored closely to detect these reactions early, 
and health facilities should be equipped to cope with the adverse effects before administration.
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Background
Dystonia is a movement disorder characterized by invol-
untary, sustained or spasmodic contractions of muscle 
groups, resulting in twisting, repetitive and abnormal 
positions [1]. Acute dystonic reactions are the most 
common type of extrapyramidal reactions associated 
with the use of metoclopramide [2]. Standard manage-
ment involves discontinuation of the drug and rapid 
intravenous or intramuscular administration of an 
anticholinergic or antihistaminic drug [3]. We present a 
case of an acute dystonic reaction in a resource limited 
setting which was managed with an oral antihistaminic 
drug.
Case presentation
A 16 year old female Muslim from the Extreme North of 
Cameroon with no significant past history was treated 
for severe malaria using intravenous quinine. Due to 
refractory nausea and vomiting she was also put on intra-
venous metoclopramide, 10 mg three times a day. A few 
minutes after administration of the second dose of meto-
clopramide, she complained of pain and stiffness of the 
neck and an inability to keep her tongue in her mouth. 
On examination, she was conscious and anxious with a 
blood pressure of 124/78 mmHg, pulse rate of 90 beats/
minute, respiratory rate of 20 breaths/minute and tem-
perature of 37.3  °C. Her neck was slightly arched back-
wards and her tongue was hanging out. There was no 
accumulation of saliva in her mouth and she could swal-
low, but with difficulty. There were no signs of respiratory 
distress. The rest of her examination was unremarkable. 
A diagnosis of metoclopramide induced acute dystonic 
reaction was made. She was administered 8  mg of oral 
chlorpheniramine. Her dystonic symptoms subsided 4 h 
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later, as did the nausea and vomiting. She continued her 
antimalarial treatment and the metoclopramide was dis-
continued. She did not have any further dystonic symp-
toms. She was discharged 2  days later and was advised 
to avoid taking metoclopramide. Follow-up visit 2 weeks 
later was unremarkable.
Conclusions
Metoclopramide hydrochloride is a dopamine receptor 
antagonist used in the management of gastrointestinal 
disorders such as nausea, vomiting and gastroparesis [4]. 
The antagonistic activity of metoclopramide at the cen-
tral and peripheral dopamine receptors gives rise to its 
anti-emetic properties. [5, 6]. Dopamine causes nausea 
and vomiting by stimulating the medullary chemore-
ceptor trigger zone. The antagonistic effect of metoclo-
pramide on dopamine receptors in the basal ganglia [5, 
7], causes an alteration in the dopaminergic-cholinergic 
balance, resulting in a deficit in central dopamine trans-
mission; and hence an excess release of acetylcholine 
over dopamine [5–7]. The incidence of metoclopramide-
induced dystonic reactions in studies carried out in the 
developed world is reported to be 1:500 patients [2, 4]. 
In the United States, over 7 million prescriptions were 
made for metoclopramide in 2004, which is over a three-
fold increase compared to the number of prescriptions 
10 years before [8]. In the developing world, very lit-
tle research has been performed on metoclopramide-
induced reactions, which is surprising given the observed 
increase in prescriptions and availability as an over the 
counter anti-emetic drug. The incidence of these reac-
tions is underestimated due to lack of data collection 
and under-reporting of cases. Female patients, children, 
adults less than 30  years of age, and patients receiving 
high doses of metoclopramide have higher chances of 
developing dystonic reactions [1, 5, 7, 9]. Our patient was 
a 16-year-old female, so compared to the general popula-
tion, she had a slightly increased risk of having a dystonic 
reaction to metoclopramide.
Following administration of metoclopramide, symp-
toms can take up to 36  h to appear, and are usually in 
the form of involuntary limb movements, facial grimac-
ing, torticollis, oculogyric crisis, rhythmic protrusion of 
the tongue, bulbar type of speech, trismus, opisthotonus 
and rarely stridor and dyspnea which result from laryn-
gospasm [5, 10].
Standard management involves discontinuation of 
metoclopramide and administration of injectable 
anticholinergic or antihistaminic drugs, most often, ben-
ztropine and diphenhydramine. The intravenous route 
is the route of choice with signs and symptoms resolv-
ing within 10  min. The intramuscular route is an alter-
native in case of inability to obtain an intravenous line, 
but it takes 30 min to be absorbed [3]. The oral route is 
the most unreliable, as oral chlorpheniramine undergoes 
extensive gut first pass metabolism with a bioavailability 
of as low as 25% and a mean peak time of up to 4 h [11].
In this case, our patient had torticollis and rhythmic 
tongue protrusion. She could not benefit from the rec-
ommended injectable anticholinergic or antihistaminic 
treatment due to unavailability of these drugs. The only 
formulation of an antihistaminic drug present at our 
institution at the time was oral chlorpheniramine. Given 
the urgency of the situation, the healthcare team could 
not waste time to arrange for referral with bad roads or 
look for appropriate drugs which are often sparsely dis-
tributed in pharmacies. Hence, she was administered 
oral chlorpheniramine which has a low bioavailabil-
ity and a slow onset of action compared to the injecta-
ble forms, and it is not too reliable in conditions which 
interfere with swallowing [5, 11]. Also, some cases of 
severe tongue protrusion dystonia are unresponsive to 
oral medications [12]. This highlights the challenges in 
resource limited settings, as not only are essential drugs 
lacking, but they lack basic resuscitation facilities, hence 
they are not equipped to handle the adverse effect of 
drugs administered in the health centers.
This case report demonstrates how unpredictable 
dystonic reactions can be, the importance of consider-
ing dystonic reactions as a possible side-effect each time 
metoclopramide is administered, and the need to be 
prepared to treat acute dystonia in facilities in which 
it is administered. It also highlights the shortcomings 
of hospitals in resource-limited settings for managing 
this adverse reaction. This is a critical issue because the 
manifestations of an acute dystonic reaction following 
the administration of an anti-emetic may be life-threat-
ening in rare instances [1, 13, 14]. Hence, health policies 
should dictate that institutions which administer meto-
clopramide and other dystonia-inducing drugs should 
be well equipped to handle their extrapyramidal adverse 
effects.
Metoclopramide is a useful drug in the management of 
nausea and vomiting related disorders and is prescribed 
by health personnel at different levels. They cause dys-
tonic reactions which do not only create an environment 
of anxiety for the patient and the care-giver, but could 
also be life threatening. Patients on metoclopramide 
should be monitored closely to detect these reactions 
early, and health facilities should be equipped to cope 
with the adverse effects before serving the drugs.
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